argenx NV ADR (ARGX)vsCrinetics Pharmaceuticals Inc (CRNX)
ARGX
argenx NV ADR
$897.85
+0.68%
HEALTHCARE · Cap: $54.94B
CRNX
Crinetics Pharmaceuticals Inc
$84.95
0.00%
HEALTHCARE · Cap: $9.01B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 13932% more annual revenue ($5.92B vs $42.16M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CRNX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$897.85
$1669.09 discount
Margin of Safety
+87.1%
Fair Value
$367.93
Current Price
$84.95
$282.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Revenue surging 2336.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 166.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -38.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : CRNX
The strongest argument for CRNX centers on Revenue Growth, Debt/Equity. Revenue growth of 2336.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CRNX
The primary concerns for CRNX are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CRNX is a hypergrowth play — different risk/reward profiles.
CRNX carries more volatility with a beta of 0.09 — expect wider price swings.
CRNX is growing revenue faster at 2336.0% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 32/100), backed by strong 31.7% margins and 52.1% revenue growth. CRNX offers better value entry with a 87.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Crinetics Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?